Targeting of single-chain urokinase plasminogen activator by conjugation to an antiplatelet antibody results in enhanced clot lysis.
Bode
C
C
Medizinische Klinik III (Kardiologie), Universität Heidelberg, Germany.
Nordt
T
T
Detlefs-Bartels
U
U
Runge
M S
MS
Arens
M
M
Kübler
W
W
Haber
E
E
D000906:Antibodies / Q000008:administration & dosage*; D001792:Blood Platelets / Q000187:drug effects / Q000276:immunology*; D005341:Fibrinolysin / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D015912:Thrombolytic Therapy / Q000379:methods; D013927:Thrombosis / Q000188:drug therapy; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D000906:Antibodies; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator